adipocytic

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

Rosiglitazone disrupts endosteal bone formation during distraction osteogenesis by local adipocytic infiltration.

Liu L, Aronson J, Lecka-Czernik B.SourceLaboratory for Limb Regeneration Research, Arkansas Children's Hospital Research Institute, 3 Children's Way, Little Rock, AR 72202, USA.
Bone.Bone.2013 Jan;52(1):247-58. doi: 10.1016/j.bone.2012.09.038. Epub 2012 Oct 13.
Rosiglitazone (Rosi) is a drug in the thiazolidinedione class for treatment of type 2 diabetes mellitus (T2DM), which binds and activates PPARγ nuclear receptor in fat cells, sensitizing them to insulin. Despite proven antidiabetic efficacy, Rosi therapy may be associated with trabecular bone loss
PMID 23069375

Influence of select extracellular matrix proteins on mesenchymal stem cell osteogenic commitment in three-dimensional contexts.

Becerra-Bayona S, Guiza-Arguello V, Qu X, Munoz-Pinto DJ, Hahn MS.SourceMaterials Science and Engineering Program, Texas A&M University, College Station, TX, USA.
Acta biomaterialia.Acta Biomater.2012 Dec;8(12):4397-404. doi: 10.1016/j.actbio.2012.07.048. Epub 2012 Aug 5.
Growth factors have been shown to be powerful mediators of mesenchymal stem cell (MSC) osteogenic differentiation. However, their use in tissue engineered scaffolds not only can be costly but also can induce undesired responses in surrounding tissues. Thus, the ability to specifically promote MSC os
PMID 22871641